EcoDrugPlus

P2x Purinoceptor 3-Like

Ensembl ID : ENSAOCG00000010949
Gene Symbol: LOC111576494
3 Cross references
194 Possible Orthologues:

P2y Purinoceptor 12-Like

Ensembl ID : ENSAOCG00000010451
Gene Symbol: LOC111575845
3 Cross references
182 Possible Orthologues:

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSAOCG00000018973
Gene Symbol: PIM3
3 Cross references
196 Possible Orthologues:

Rac-Beta Serine/threonine-Protein Kinase

Ensembl ID : ENSAOCG00000005345
Gene Symbol: LOC111566093
3 Cross references
199 Possible Orthologues:

Rac-Beta Serine/threonine-Protein Kinase-Like

Ensembl ID : ENSAOCG00000000646
Gene Symbol: LOC111584424
3 Cross references
185 Possible Orthologues:

Rac-Gamma Serine/threonine-Protein Kinase

Ensembl ID : ENSAOCG00000007768
Gene Symbol: LOC111581166
3 Cross references
203 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSAOCG00000007076
Gene Symbol: RAF1
3 Cross references
207 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSAOCG00000008248
Gene Symbol: ROCK1
3 Cross references
212 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSAOCG00000002618
Gene Symbol: ROCK2
3 Cross references
216 Possible Orthologues:

Sem1 26s Proteasome Complex Subunit

Ensembl ID : ENSAOCG00000015143
Gene Symbol: SEM1
3 Cross references
156 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSAOCG00000009110
Gene Symbol: SRC
3 Cross references
191 Possible Orthologues:

Tgf-Beta Receptor Type-1-Like

Ensembl ID : ENSAOCG00000005348
Gene Symbol: LOC111569578
3 Cross references
205 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).